MedTrace Logo

Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases

NCT01252901 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2015-05-28

No results posted yet for this study

Summary

The Wilms' tumor suppressor gene 1 (WT1) encodes for a transcription factor which plays an important role during urogenital development. Patients carrying a WT1 germline mutation show symptoms like proteinuria, Wilms tumors, genital malformations and kidney failure. Milder variants are possible and classification is not always possible. In this registry we are collecting detailed clinical data of affected individuals to establish genotype-phenotype correlations with the greater goal to optimize patient care.

Conditions

  • Denys-Drash Syndrome
  • Frasier Syndrome
  • Nephrotic Syndrome
  • Wilms Tumor

Sponsors & Collaborators

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Principal Investigators

  • Anja Lehnhardt, MD · Universitätsklinikum Hamburg-Eppendorf

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2013-11-30
Completion
2014-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01252901 on ClinicalTrials.gov